Christopher Porter

Jul 18, 2024 | nature.com | Olivier Saulnier |Paul Jerard Layug |Kimberly A Aldinger |Christopher Porter |Stephane Richard |Brad Doble | +1 more

AbstractOTX2 is a transcription factor and known driver in medulloblastoma (MB), where it is amplified in a subset of tumours and overexpressed in most cases of group 3 and group 4 MB. Here we demonstrate a noncanonical role for OTX2 in group 3 MB alternative splicing. OTX2 associates with the large assembly of splicing regulators complex through protein–protein interactions and regulates a stem cell splicing program.

Sep 19, 2023 | nature.com | Christopher Porter |Vijay Ramaswamy

AbstractSonic Hedgehog (SHH) medulloblastomas (MBs) exhibit an intermediate prognosis and extensive intertumoral heterogeneity. While SHH pathway antagonists are effective in post-pubertal patients, younger patients exhibit significant side effects, and tumors that harbor mutations in downstream SHH pathway genes will be drug resistant. Thus, novel targeted therapies are needed.

May 6, 2023 | nationalinterest.org | Christopher Porter

It is worth remembering, more than a year into Russia’s war in Ukraine, that the conflict was initiated not by an artillery shell or missile or any kinetic action, but with a cyberattack on the Ukrainian financial system with the deliberate aim of terrorizing Ukrainian citizens alongside more conventional cyberattacks on the Ukrainian Defence Ministry, according to Ukrainian intelligence services.